STOCK TITAN

Vanguard Portfolio Management (KRYS) Discloses 5.05% Holding in Krystal Biotech

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Krystal Biotech Inc ownership filing: Vanguard Portfolio Management reports beneficial ownership of 1,479,111 shares of Common Stock, representing 5.05% of the class. The filing states Vanguard has sole dispositive power over 1,479,111 shares and sole voting power for 22,384 shares.

The disclosure attributes holdings to Vanguard Portfolio Management and identified affiliates and notes these positions include shares held for Vanguard funds and managed accounts.

Positive

  • None.

Negative

  • None.

Insights

Vanguard reports a >5% stake, signalling notable passive ownership.

Vanguard Portfolio Management discloses beneficial ownership of 1,479,111 shares or 5.05% of Krystal Biotech common stock, with sole dispositive power over the full amount and limited sole voting power on 22,384 shares. The filing attributes holdings to Vanguard and affiliates, including funds and managed accounts.

Because this is a Schedule 13G disclosure, the position is presented as passive under the form's standards. Subsequent filings would show changes; current cash‑flow treatment or trading intentions are not stated in the excerpt.

Beneficial ownership 1,479,111 shares Amount beneficially owned reported on Schedule 13G
Percent of class 5.05% Percent of common stock class reported
Sole voting power 22,384 shares Shares for which Vanguard has sole power to vote
Sole dispositive power 1,479,111 shares Shares for which Vanguard has sole power to dispose
Filing attestation date 04/29/2026 Signature date on Schedule 13G
Schedule 13G regulatory
"Schedule 13G reporting beneficial ownership of the issuer"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Beneficially owned financial
"Amount beneficially owned: 1479111"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Dispositive power regulatory
"Sole power to dispose or to direct the disposition of: 1479111"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
Sole voting power regulatory
"Sole power to vote or to direct the vote: 22384"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stake does Vanguard report in Krystal Biotech (KRYS)?

Vanguard Portfolio Management reports beneficial ownership of 1,479,111 shares, equal to 5.05% of Krystal Biotech's common stock as stated in the filing.

Does Vanguard control voting of all reported Krystal Biotech shares?

No. Vanguard reports sole voting power for 22,384 shares and sole dispositive power for 1,479,111 shares, indicating voting and dispositive powers differ in scale.

Which Vanguard entities are tied to the reported ownership?

The filing lists Vanguard Portfolio Management LLC and affiliates, including Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC, as having exercisable dispositive or voting power over the reported shares.

Is the Vanguard position reported as passive or active?

The position is disclosed on a Schedule 13G, which is used for passive investors; the filing presents the stake as passive rather than an active acquisition statement.

Who signed the Schedule 13G for Vanguard?

The filing is signed by Ashley Grim, Head of Global Fund Administration, with an attestation date of 04/29/2026 as shown in the document.





501147102

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Portfolio Management LLC and the following affiliates of Vanguard Portfolio Management LLC or business divisions of such affiliates: Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Portfolio Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Portfolio Management LLC, or business divisions of such subsidiaries whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.


SCHEDULE 13G



Vanguard Portfolio Management
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:04/29/2026